Abiraterone acetate - Johnson & Johnson
At a glance
- Drug Originator The Institute of Cancer Research
- Drug Licenced by Janssen Research & Development; Johnson & Johnson
- Drug Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors
- USA Patent Applicants JANSSEN BIOTECH
- USA Patents 2
- NDAs 1
- Patent Applications 2,342
Table of Contents
Disclaimer